Skip to content

Study · Not a test of the peptide alone · 2026

2 results

In silico prediction of the lipid-lowering efficacy of the oral PCSK9 inhibitor enlicitide using a mechanistic computational model.

Cariou B, Wang Y, Angoulvant D, Boccara F, Mahé G, Steg PG, Bechet E

Atherosclerosis13 Feb 2026

PMID41702283 (opens in a new tab)DOI10.1016/j.atherosclerosis.2026.120682 (opens in a new tab)PepBankPUB-41702283
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Enlicitide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Enlicitide.

  1. 01Computer modelNot a test of Enlicitide aloneIn silicoEfficacy outcome

    In a computational model, enlicitide produced a predicted LDL-C reduction of -54.5% at week 24 for CORALreef Lipids.

    In plain wordsIn a computer model, enlicitide was predicted to reduce LDL-C at week 24.

    Peptide
    Enlicitide
    Outcome
    DecreasePredicted LDL-C reduction at week 24
    Study

    n: not reported in source

    mechanistic QSP model of atherosclerosis
    Outcome group
    Lipids · Metabolic and weight

    Measurements

    Predicted LDL-C reduction
    −54.5%
    week 24

    Source sentences

    Summary
    For CORALreef Lipids, the predicted week-24 LDL-C reduction was -54.5% (95% PPI: -56.1%, -53.0%), closely matching the subsequently reported -55.8% (95% CI: -60.9%, -50.7%).
    1 context sentence
    Summary · context
    The model was recalibrated using phase 1 PK/PD data and phase 2b LDL-C response data to incorporate enlicitide's effect.

    In this study, Enlicitide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Enlicitide.

  2. 02Computer modelNot a test of Enlicitide aloneIn silicoEfficacy outcome

    In a computational model, the predicted LDL-C reduction with enlicitide was -59.4% at week 8 for CORALreef AddOn.

    In plain wordsIn a computer model, enlicitide was predicted to reduce LDL-C at week 8.

    Peptide
    Enlicitide
    Outcome
    DecreasePredicted LDL-C reduction at week 8
    Study

    n: not reported in source

    mechanistic QSP model of atherosclerosis
    Outcome group
    Lipids · Metabolic and weight

    Measurements

    Predicted LDL-C reduction
    −59.4%
    week 8

    Source sentences

    Summary
    For CORALreef AddOn, predicted week-8 LDL-C reductions were -59.4% (95% PPI: -65.7, -53.4) with enlicitide
    1 context sentence
    Summary · context
    The model was recalibrated using phase 1 PK/PD data and phase 2b LDL-C response data to incorporate enlicitide's effect.

    In this study, Enlicitide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Enlicitide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.